Diabetes drugs and cardiovascular safety

Endocrinology and Metabolism

Volumn 31, Issue 2, 2016, Pages 239-244

  Bae, Ji Cheol ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Heart failure; Hypoglycemic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; VILDAGLIPTIN;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; META ANALYSIS (TOPIC); MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 84976645390     PISSN: 2093596X     EISSN: 20935978     Source Type: Journal    
DOI: 10.3803/EnM.2016.31.2.239     Document Type: Review

References (44)

1. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10:289-301.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
3. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014;384: 1936-41.
4. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
5. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372:2197-206.
6. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304:411-8.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
8. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36.
9. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092-5.
10. Bailey CJ. Interpreting adverse signals in diabetes drug development programs. Diabetes Care 2013;36:2098-106.
11. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81.
12. Bloomgarden ZT. The Avandia debate. Diabetes Care 2007; 30:2401-8.
13. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2013;128:785-94.
14. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
15. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
16. European Medicines Agency. European Medicines Agency recommends suspension of avandia, avandamet and avaglim [Internet]. London: European Medicines Agency; c2016 [cited 2016 May 24]. Available from: http://ema.europa. eu/ema/index.jsp?curl=pages/news_and_events/ news/2010/09/news_detail_001119.jsp.
17. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363:1489-91.
18. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35.
19. U.S. Food and Drug Administration. FDA drug safety communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines [Internet]. Silver Spring: U.S. Food and Drug Administration; 2016 [cited 2016 May 24]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm.
20. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitusevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Silver Spring: U.S. Food and Drug Administration; 2016 [cited 2016 May 24]. Available from: http://www.fda.gov/downloads/Drug/ GuidanceComplianceRegulatoryInformation/%20Guidances/ ucm071627.psd.
21. Menon V, Lincoff AM. Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus. Circulation 2014;129:2705-13.
22. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.
23. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-31.
24. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.
25. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327-35.
26. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
27. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
28. Standl E. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;370:483.
29. Standl E, Schnell O. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 2015;385:2022-4.
30. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579-88.
31. McMurray J. Effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure. Paper presented at: Heart Failure Congress 2013; May 25-28; Lisbon, Portugal.
32. Fonarow GC. Diabetes medications and heart failure: recognizing the risk. Circulation 2014;130:1565-7.
33. Bhatt DL, Cavender MA. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? JACC Heart Fail 2014; 2:583-5.
34. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014;32:147-58.
35. Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clin Ther 2014;36:2072-9.
36. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015;3:356-66.
37. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:126-35.
38. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-57.
39. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009;32 Suppl 2:S223-31.
40. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117-28.
41. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 2016;89:524-6.
42. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12:90-100.
43. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
44. Cernea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 2011;8:323-38.